Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Authors: Long Huang, Ling-Min Liao, An-Wen Liu, Jian-Bing Wu, Xiao-Ling Cheng, Jia-Xin Lin, Min Zheng

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Small cell cervical carcinoma (SCCC) is a rare, aggressive tumor with a poor prognosis. However, information in relation to its treatment is scarce due to the limited numbers of patients. The aim of this study was to establish whether platinum-based combination chemotherapy may by beneficial in this patient population.

Methods

We carried out a multicenter, retrospective study comprising of 72 Chinese patients with SCCC. The patients were treated between 1995 and 2010 at Sun Yat-sen Memorial Hospital or the Cancer Center of Sun Yat-Sen University, and at the First Affiliated Hospital of Shantou University Medical College, China.

Results

Of the 72 patients, 46/72 (63.9%) had Federation of Gynecology and Obstetrics (FIGO) stage Ia–Ib2 and 26/72 (36.1%) had stage IIa–IV disease. Surgery was performed in 63/72 (87.5%) patients, 61/72 (84.7%) patients received chemoradiotherapy and 35/72 (48.6%) received radiotherapy. The 3-year overall survival (OS) and disease-free survival (DFS) rates were as follows: Ia (100%, 100%); Ib1 (62%, 57%); Ib2 (53%, 48%); IIa (36%, 23%); IIb (29%, 21%); IIIb (50%, 50%); and IV (0%, 0%), respectively. The estimated 3-year OS and DFS rates in patients who received platinum-based combination chemotherapy (etoposide + cisplatin [EP], or paclitaxel + cisplatin [TP]) as part of their adjuvant treatment were 64.8% and 63.0%, respectively, compared to 25.2% and 22.0% in those who did not (P = 0.0003; P = 0.0003). Univariate analysis showed that platinum-based combination chemotherapy was associated with improved survival compared to other chemotherapy techniques or no chemotherapy (OS: HR = 0.227; 95% CI, 0.099–0.524; P = 0.001; DFS: HR = 0.210; 95% CI, 0.087–0.506; P = 0.001). Multivariate analysis identified FIGO stage, lymphatic metastasis and platinum-based combination chemotherapy as independent prognostic factors for improved survival in patients with SCCC.

Conclusions

Platinum-based combination chemotherapy (with EP or TP) can improve the 3-year survival outcomes in patients with SCCC. Therefore, it should be considered an important component in a future standardized treatment strategy for SCCC.
Appendix
Available only for authorised users
Literature
1.
Crowder S, Tuller E: Small cell carcinoma of the female genital tract. Semin Oncol. 2007, 34 (1): 57-63. 10.1053/j.seminoncol.2006.10.028.CrossRefPubMed
2.
Chung HH, Jang MJ, Jung KW, Won YJ, Shin HR, Kim JW, Lee HP: Members for gynecologic oncology committee of Korean society of obstetrics and gynecology: cervical cancer incidence and survival in Korea: 1993–2002. Int J Gynecol Cancer. 2006, 16 (5): 1833-1838. 10.1111/j.1525-1438.2006.00708.x.CrossRefPubMed
3.
Tsunoda S, Jobo T, Arai M, Imai M, Kanai T, Tamura T, Watanabe J, Obokata A, Kuramoto H: Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases. Int J Gynecol Cancer. 2005, 15 (2): 295-300. 10.1111/j.1525-1438.2005.15219.x.CrossRefPubMed
4.
Sykes AJ, Shanks JH, Davidson SE: Small cell carcinoma of the uterine cervix: a clinicopathological review. Int J Oncol. 1999, 14 (2): 381-386.PubMed
5.
Miller B, Dockter M, el Torky M, Photopulos G: Small cell carcinoma of the cervix: a clinical and flow-cytometric study. Gynecol Oncol. 1991, 42 (1): 27-33. 10.1016/0090-8258(91)90225-T.CrossRefPubMed
6.
Sheets EE, Berman ML, Hrountas CK, Liao SY, DiSaia PJ: Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol. 1988, 71 (1): 10-14.PubMed
7.
Randall ME, Kim JA, Mills SE, Hahn SS, Constable WC: Uncommon variants of cervical carcinoma treated with radical irradiation. A clinicopathologic study of 66 cases. Cancer. 1986, 57 (4): 816-822. 10.1002/1097-0142(19860215)57:4<816::AID-CNCR2820570423>3.0.CO;2-Z.CrossRefPubMed
8.
Albores-Saavedra J, Larraza O, Poucell S, Rodríguez Martínez HA: Carcinoid of the uterine cervix: additional observations on a new tumor entity. Cancer. 1976, 38 (6): 2328-2342. 10.1002/1097-0142(197612)38:6<2328::AID-CNCR2820380620>3.0.CO;2-J.CrossRefPubMed
9.
Liao LM, Zhang X, Ren YF, Sun XY, Di N, Zhou N, Pan RK, Ma SH, Zhou LX: Chromogranin A (CgA) as poor prognostic factor in patients with small cell carcinoma of the cervix: results of a retrospective study of 293 patients. PLoS One. 2012, 7 (4): e33674-10.1371/journal.pone.0033674.CrossRefPubMedPubMedCentral
10.
Morris M, Gershenson DM, Eifel P, Silva EG, Mitchell MF, Burke TW, Wharton JT: Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecol Oncol. 1992, 47 (1): 62-65. 10.1016/0090-8258(92)90077-V.CrossRefPubMed
11.
Stoler MH, Mills SE, Gersell DJ, Walker AN: Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol. 1991, 15 (1): 28-32. 10.1097/00000478-199101000-00003.CrossRefPubMed
12.
Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, Chen LM, Osann K, Chan JK: Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010, 203 (4): 347.e1-347.e6.CrossRef
13.
Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ: Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer. 2003, 97 (3): 568-574. 10.1002/cncr.11086.CrossRefPubMed
14.
Abeler VM, Holm R, Nesland JM, Kjørstad KE: Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer. 1994, 73 (3): 672-677. 10.1002/1097-0142(19940201)73:3<672::AID-CNCR2820730328>3.0.CO;2-R.CrossRefPubMed
15.
Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M: Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012, 7 (3): e33762-10.1371/journal.pone.0033762.CrossRefPubMedPubMedCentral
16.
Sevin BU, Method MW, Nadji M, Lu Y, Averette HA: Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer. 1996, 77 (8): 1489-1493. 10.1002/(SICI)1097-0142(19960415)77:8<1489::AID-CNCR10>3.0.CO;2-W.CrossRefPubMed
17.
Gersell DJ, Mazoujian G, Mutch DG, Rudloff MA: Small-cell undifferentiated carcinoma of the cervix. A clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol. 1988, 12 (9): 684-698. 10.1097/00000478-198809000-00005.CrossRefPubMed
18.
Pazdur R, Bonomi P, Slayton R, Gould VE, Miller A, Jao W, Dolan T, Wilbanks G: Neuroendocrine carcinoma of the cervix: implications for staging and therapy. Gynecol Oncol. 1981, 12 (1): 120-128. 10.1016/0090-8258(81)90103-7.CrossRefPubMed
19.
Van Nagell JR, Jr Donaldson ES, Wood EG, Maruyama Y, Utley J: Small cell cancer of the uterine cervix. Cancer. 1977, 40 (5): 2243-2249. 10.1002/1097-0142(197711)40:5<2243::AID-CNCR2820400534>3.0.CO;2-H.CrossRefPubMed
20.
Piver MS, Rutledge F, Smith JP: Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974, 44 (2): 265-272.PubMed
21.
Kuji S, Hirashima Y, Nakayama H, Nishio S, Otsuki T, Nagamitsu Y, Tanaka N, Ito K, Teramoto N, Yamada T: Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan. Gynecol Oncol. 2013, 129 (3): 522-527. 10.1016/j.ygyno.2013.02.025.CrossRefPubMed
22.
Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, Kato H: Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005, 129 (5): 977-983. 10.1016/j.jtcvs.2004.05.030.CrossRefPubMed
23.
Leo F, Pastorino U: Surgery in small-cell lung carcinoma. Where is the rationale?. Semin Surg Oncol. 2003, 21 (3): 176-181. 10.1002/ssu.10035.CrossRefPubMed
24.
Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, Brahmer J, Rudin CM, Ettinger DS, Yang SC: Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg. 2005, 129 (1): 64-72. 10.1016/j.jtcvs.2004.08.022.CrossRefPubMed
25.
Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N: Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003, 21 (18): 3495-3501. 10.1200/JCO.2003.01.501.CrossRefPubMed
26.
Zivanovic O, Leitao MM, Park KJ, Zhao H, Diaz JP, Konner J, Alektiar K, Chi DS, Abu-Rustum NR, Aghajanian C: Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol. 2009, 112 (3): 590-593. 10.1016/j.ygyno.2008.11.010.CrossRefPubMed
27.
Gardner GJ, Reidy-Lagunes D, Gehrig PA: Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011, 122 (1): 190-198. 10.1016/j.ygyno.2011.04.011.CrossRefPubMed
28.
Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB: Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008, 19 (2): 321-326. 10.1093/annonc/mdm465.CrossRefPubMed
29.
Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM, Wu HH, Liou WS, Hsu ST, Ou YC, Yeh LS, Lai HC, Huang CY, Chen TC, Chang CJ, Lai CH: Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer. 2012, 48 (10): 1484-1494. 10.1016/j.ejca.2011.12.014.CrossRefPubMed
Metadata
Title
Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients
Authors
Long Huang
Ling-Min Liao
An-Wen Liu
Jian-Bing Wu
Xiao-Ling Cheng
Jia-Xin Lin
Min Zheng
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-140

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis

Research article

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

Research article

Using technology to deliver cancer follow-up: a systematic review

Research article

Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma

Research article

Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection

Research article

Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits